← Back to Search

Behavioral Intervention

Storytelling Intervention for Atrial Fibrillation

N/A

Waitlist Available

Led By Alok Kapoor, MD

Research Sponsored by University of Massachusetts, Worcester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Patients with left atrial appendage surgery or device, hospice status, ongoing bleeding, and intracranial bleeding in intralobar territory

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months from randomization

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to help treat atrial fibrillation & lower stroke risks for African American & Black patients by increasing use of anticoagulants.

Who is the study for?

This trial is for African American and Black patients, 18 or older with a risk of stroke who are recommended but not yet on anticoagulation therapy. It's not for those under 18, non-African Americans, pregnant women, prisoners, or individuals with certain bleeding disorders or recent brain surgery.

What is being tested?

The study tests the impact of storytelling as an intervention to encourage the use of blood thinners in African American and Black patients with atrial fibrillation/flutter to reduce their stroke risk.

What are the potential side effects?

While this trial focuses on storytelling rather than medication side effects directly, generally speaking, anticoagulants can increase the risk of bleeding complications.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have not had surgery on my heart's left atrial appendage, am not in hospice, and do not have ongoing or recent serious bleeding.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months from randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months from randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months from randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Acceptability of participating in the study

Feasibility in terms of recruitment rates

Feasibility in terms of retention rates

+4 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention - Patient VideosExperimental Treatment1 Intervention

Videos of African Americans currently taking anticoagulation talking about their experiences with using anticoagulation or blood thinners and successfully navigating setbacks occurring with use including bleeding, falls, strokes, and affording the medications.

Group II: Control - Informational Videos (not patients)Active Control1 Intervention

Informational videos about anticoagulation and blood thinners presented by experts or actors.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Storytelling Intervention

2023

N/A

~80

0 / 1Eligibility criteria met